

Extended Data Figure 1 | Post Vaccination Changes in Lymphocyte Count Over Time. Figure represents box-and-whisker plots for observed values at the following timepoints: Dose 1/Day 1-3: \sim 1 day after Dose 1; Dose 2/Day 6-8: \sim 7 days after Dose 1; Pre-Dose 2: before Dose 2; Dose 2/Day 6-8: \sim 7 days after Dose 2. Symbols denote group means – O: placebo; +: 10 μ g; X: 30 μ g; \triangle : 100 μ g. Center line of box denotes median; lower and upper edges denote first and third quartiles; lower and upper whiskers denote minimum and maximum.

	10 μg (N=12) n (%)	30 μg (N=12) n (%)	100 μg (N=12) n (%)	Placebo (N=9) n (%)	Total (N=45) n (%)
Sex					
Male	7 (58.3)	6 (50.0)	5 (41.7)	5 (55.6)	23 (51.1)
Female	5 (41.7)	6 (50.0)	7 (58.3)	4 (44.4)	22 (48.9)
Race					
White	8 (66.7)	10 (83.3)	11 (91.7)	8 (88.9)	37 (82.2)
Black or African American	1 (8.3)	0	0	0	1 (2.2)
Asian	3 (25.0)	2 (16.7)	1 (8.3)	1 (11.1)	7 (15.6)
Ethnicity					
Hispanic/Latino	1 (8.3)	1 (8.3)	0	0	2 (4.4)
Non-Hispanic/non-Latino	11 (91.7)	10 (83.3)	12 (100.0)	9 (100.0)	42 (93.3)
Not reported	0	1 (8.3)	0	0	1 (2.2)
Age at vaccination (years)					
Mean (SD)	29.4 (6.39)	35.8 (9.96)	38.3 (9.34)	39.0 (11.16)	35.4 (9.71)
Median	26.5	33.5	38.0	41.0	33.0

Extended Data Table 1 | Demographic Characteristics. N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations. n = Number of subjects with the specified characteristic.

(23, 52)

(25, 53)

(19, 54)

(19, 54)

(24, 42)

Min, max

	10 μg (N=12)	30 μg (N=12)	100 μg (N=12)	Placebo (N=9)
Adverse Event	n (%)	n (%)	n (%)	n (%)

Any event	6 (50.0)	6 (50.0)	7 (58.3)	1 (11.1)
Related	3 (25.0)	6 (50.0)	6 (50.0)	1 (11.1)
Severe	0	1 (8.3)	1 (8.3)	0
Life-threatening	0	0	0	0
Any serious adverse event	0	0	0	0
Related	0	0	0	0
Severe	0	0	0	0
Life-threatening	0	0	0	0
Any adverse event leading to withdrawal	0	0	0	0
Related	0	0	0	0
Severe	0	0	0	0
Life-threatening	0	0	0	0
Death	0	0	0	0

Extended Data Table 2 | **Adverse Events.** N: number of subjects in the specified group or the total sample. This value is the denominator for the percentage calculations. n: number of subjects reporting at least 1 occurrence of the specified adverse event category. For "any event", n: the number of subjects reporting at least 1 occurrence of any adverse event; Related: Assessed by the investigator as related to investigational product.